Can You Start Wegovy at 0.5 mg? Why the Label Starts Lower

    Can You Start Wegovy at 0.5 mg? Why the Label Starts Lower

    No. The 2026 FDA label starts Wegovy at 0.25 mg weekly (pill 1.5 mg daily) to limit nausea. Titration, missed doses, Ozempic switching and 7.2 mg explained.

    Written by Diana Gangan. Updated November 4, 2026.

    No. The current FDA label for Wegovy (revised June 2026) starts every new patient on the injection at 0.25 mg once a week, or on the Wegovy pill at 1.5 mg once a day, and raises the dose in steps specifically to reduce gastrointestinal side effects such as nausea, vomiting and diarrhea. The label gives no option to begin at 0.5 mg, so any change to that schedule is a decision for your prescriber, not something to do on your own. Wegovy is semaglutide, a GLP-1 drug that lowers appetite and slows stomach emptying, which is also why starting too high can make people feel sick. This guide quotes what the label actually says, explains why so many people were told to start at 0.5 mg during the 2023 to 2025 shortage, and covers missed doses, the pill, the 7.2 mg dose and switching from Ozempic, as of November 2026.

    Can You Start Wegovy at 0.5 mg? The Short Answer

    1. 1Label starting dose: 0.25 mg injection once weekly for weeks 1 to 4, or 1.5 mg pill once daily for days 1 to 30.
    2. 2Why it starts low: the label says the step-up schedule is there 'to reduce the risk of gastrointestinal adverse reactions'.
    3. 3No label route to start at 0.5 mg; only switches between Wegovy injection and Wegovy pill skip the escalation.
    4. 4Missed 2 or more weekly doses in a row: the 2026 label says to restart escalation 'at a lower dosage', but does not say which one.
    5. 5Switching from Ozempic: the Wegovy label gives no conversion; your prescriber decides the starting dose.
    6. 67.2 mg is never a starting dose: it requires at least 4 weeks on 2.4 mg first.

    What Does the Wegovy Label Say the Starting Dose Is?

    The wording is direct: 'The recommended starting dosage of WEGOVY injection is 0.25 mg administered subcutaneously once weekly.' Subcutaneously means injected just under the skin. The label then tells prescribers to 'follow the dosage escalation in Table 1 to reduce the risk of gastrointestinal adverse reactions.' Escalation (titration) means raising the dose step by step. For the injection, each step lasts four weeks: 0.25 mg, then 0.5 mg, then 1 mg, then 1.7 mg, reaching a maintenance dose from week 17. For the Wegovy pill, each step lasts 30 days. The full week-by-week calendar is in our Wegovy dosing schedule guide, and the table below summarizes it.

    Wegovy dose escalation on the FDA label (revised June 2026)

    Step
    Injection (once weekly)
    Pill (once daily)

    Start

    Weeks 1 to 4: 0.25 mg

    Days 1 to 30: 1.5 mg

    Step 2

    Weeks 5 to 8: 0.5 mg

    Days 31 to 60: 4 mg

    Step 3

    Weeks 9 to 12: 1 mg

    Days 61 to 90: 9 mg

    Step 4

    Weeks 13 to 16: 1.7 mg

    Day 91 onward: 25 mg (maintenance)

    Maintenance

    Week 17 onward: 2.4 mg (recommended) or 1.7 mg for adult weight reduction

    25 mg; if not tolerated, the label says to consider switching to the 1.7 mg weekly injection

    Higher option

    7.2 mg weekly, adults only, after at least 4 weeks on 2.4 mg if more weight loss is clinically indicated

    None

    If a step is not tolerated

    Consider delaying the next increase for 4 weeks

    Consider delaying the next increase

    Maintenance depends on why Wegovy is prescribed. For adult weight reduction it is 2.4 mg (recommended) or 1.7 mg; for teenagers 12 and older it is 2.4 mg or 1.7 mg; for lowering heart attack and stroke risk it is 2.4 mg or 1.7 mg; and for MASH, a form of fatty liver disease, it is 2.4 mg. How the doses compare is covered in Wegovy maintenance dose.

    Why Does Wegovy Start at 0.25 mg?

    Because stomach and gut side effects are common and are concentrated in the escalation period. In the label's adult weight trials at 2.4 mg, 73% of people on Wegovy reported a gastrointestinal side effect compared with 47% on placebo. Nausea affected 44% against 16%, diarrhea 30% against 16%, vomiting 24% against 6%, constipation 24% against 11% and abdominal pain 20% against 10%. Severe gastrointestinal events occurred in 4.1% against 0.9%, and 4.3% stopped treatment because of them, against 0.7% on placebo. The label notes these effects were 'most frequently reported during dosage escalation.'

    A pooled analysis of the STEP 1 to 3 trials (Wharton and colleagues, 2021, funded by Novo Nordisk) found that 98.1% of gastrointestinal events were mild to moderate, 99.5% were non-serious, and most occurred during or shortly after a dose increase and then faded. For the pill, the label reports severe gastrointestinal events in 2% against 0% on placebo and stops for these reasons in 3.4% against 2%.

    Can I Start Wegovy at 0.5 mg Under the Label?

    No. We checked the June 2026 label and found no wording that allows starting the injection above 0.25 mg or the pill above 1.5 mg. The only flexibility it gives runs the other way: 'If patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation for 4 weeks.' The label allows going slower, not faster.

    Some people end up staying on a lower step for longer with their prescriber's agreement, which is a different question from starting high; see can you stay on a low dose of Wegovy. Taking tiny off-label amounts is a separate idea again, discussed in microdosing GLP-1 drugs.

    What Happens If You Skip 0.25 mg of Wegovy?

    We found no clinical trial that tested starting Wegovy above 0.25 mg or raising the dose faster than the label, so there is no direct data on what skipping the first step does. What the label data do show is that gastrointestinal side effects are frequent and cluster around dose increases; starting at 0.5 mg means taking a bigger first step without the four weeks of adjustment the schedule is designed to provide.

    The only randomized evidence on titration speed points toward going slower. A 2025 open-label pilot trial from Tel Aviv published in Diabetes Care enrolled 104 adults with type 2 diabetes taking Ozempic, not Wegovy, at doses up to 1 mg. A flexible 16-week schedule that started at 0.0675 mg was compared with the standard 8-week Ozempic schedule. Stops due to gastrointestinal side effects were 2% against 19%, nausea was reported by 45.1% against 64.2% (a difference that did not quite reach statistical significance), and nausea lasted an average of 2.88 against 6.3 days. Being small, open-label and in diabetes with Ozempic, it cannot be applied directly to Wegovy, but it does not support starting higher.

    Is a Missed Dose a Reason to Restart at 0.25 mg?

    It depends on how many doses you missed. The June 2026 label is stricter than the original 2021 wording. For a single missed injection, it uses a two-day rule; if two or more weekly doses in a row are missed, it says: 'reinitiate dosage escalation at a lower dosage to reduce the risk of gastrointestinal adverse reactions.' Note what the label does not say: it does not name 0.25 mg or any other specific dose, and it does not use a 'more than two weeks' rule. Which lower dose to restart on is left to your prescriber. The 2021 label had allowed patients to 'resume dosing as scheduled or, if needed, reinitiate' Wegovy.

    Wegovy missed-dose rules on the FDA label (revised June 2026)

    Situation
    What the label says

    Injection: 1 dose missed, next dose more than 2 days away

    'Administer WEGOVY injection as soon as possible'

    Injection: 1 dose missed, next dose less than 2 days away

    'Do not administer the WEGOVY injection dose'

    Injection: after a single missed dose

    'Resume dosing on the regularly scheduled day of the week'

    Injection: 2 or more consecutive doses missed

    'Reinitiate dosage escalation at a lower dosage to reduce the risk of gastrointestinal adverse reactions' (lower dose not specified)

    Pill: 1 dose missed

    'Skip the missed dose and take the next dose the following day'

    If you stopped for longer, what to expect after stopping is in what happens when you stop taking Wegovy.

    Switching From Ozempic to Wegovy: What Dose Do You Start On?

    The Wegovy label does not say. We checked the June 2026 version and it contains no instructions for switching from Ozempic, Rybelsus or any other GLP-1 drug. Ozempic and Wegovy contain the same molecule, semaglutide, but come in different doses, pens and approved uses; the differences are explained in Wegovy vs Ozempic. The label also states that using Wegovy together 'with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended,' so the two should not overlap. The 2021 Wegovy label noted that Ozempic's 0.5 mg and 1 mg doses had not been established for chronic weight management.

    Because there is no official conversion, we do not give one here. Your prescriber will weigh your current dose, tolerance and time since your last injection. A UK guide in the Pharmaceutical Journal suggests restarting semaglutide at 0.25 mg when switching from tirzepatide (Mounjaro or Zepbound), and notes that re-titrating may cause 'a temporary plateau' in weight loss, but it does not cover Ozempic to Wegovy.

    Can You Switch Between the Wegovy Shot and the Wegovy Pill Without Restarting?

    Yes, at maintenance, and this is the one place the label skips escalation. From the 2.4 mg injection: 'One week after discontinuing WEGOVY 2.4 mg injection, initiate 25 mg of WEGOVY tablets.' From the 25 mg pill to the injection, start 2.4 mg weekly the day after the last tablet. How the two forms compare is covered in Wegovy pill vs injection.

    How Does the Wegovy Pill Start?

    'The recommended starting dosage of WEGOVY tablets is 1.5 mg taken orally once daily.' The pill steps up every 30 days to 4 mg, 9 mg and then 25 mg from day 91. It must be taken on an empty stomach with up to 4 ounces (about 120 ml) of water, then waiting 30 minutes before eating. Novo Nordisk announced FDA approval of the pill on December 22, 2025, with US launch in early January 2026. As with the injection, there is no label option to start on a higher tablet.

    Can You Go Straight to Wegovy 7.2 mg?

    No. The FDA approved the 7.2 mg dose (sold as Wegovy HD) on March 19, 2026, for weight reduction in adults only. The label allows it 'for patients who tolerate the 2.4 mg dosage for at least 4 weeks' when 'additional weight reduction is clinically indicated', with the dose 'increased to a maximum dosage of 7.2 mg' weekly. In the STEP UP trial reported on the label, nausea occurred in 39% on 7.2 mg, 35% on 2.4 mg and 13% on placebo, and vomiting in 22%, 16% and 6%. The multi-dose FlexTouch pen (9.6 mg in 3 mL, four 2.4 mg doses) is for maintenance only and should never be shared; it does not come in a 0.25 mg strength. How to use the single-dose pens is in how to use the Wegovy pen.

    Why Were People Told to Start Wegovy at 0.5 mg?

    Mostly because of supply. On May 4, 2023, Novo Nordisk said it was restricting shipments of the 0.25 mg, 0.5 mg and 1 mg Wegovy pens to US wholesalers and expected that many patients would have difficulty filling prescriptions at those doses through September. With the lowest pens hard to find, the question 'can I start at 0.5 mg?' spread online. The FDA declared the semaglutide shortage resolved on February 21, 2025. We found no 2026 source reporting a current US shortage of 0.25 mg pens, so a missing starter pen is no longer a routine reason to begin higher.

    Does Starting Low Slow Down Weight Loss?

    Weight loss in the trials behind Wegovy's approval was measured using the label's 16-week escalation, so the reported results already include the slow start. There is no trial showing that starting at 0.5 mg leads to more weight loss in the end. In the STEP pooled analysis, less than one percentage point of weight loss was attributed to gastrointestinal side effects, so feeling sick is not what drives results. What you can realistically expect month by month is in how long does Wegovy take to work.

    When to Talk to Your Doctor

    1. 1You were given or advised to start at 0.5 mg or higher, and want to understand why.
    2. 2You have missed two or more weekly injections in a row.
    3. 3You are switching from Ozempic, Rybelsus, Zepbound, Mounjaro or another GLP-1 drug.
    4. 4Nausea, vomiting or diarrhea stop you eating or drinking normally, or you show signs of dehydration.
    5. 5You have severe or persistent stomach pain.
    6. 6You cannot fill your prescribed dose and are tempted to use a different strength.

    What to Do Next: Questions to Ask Your Doctor

    1. 1Is there a medical reason for me to start at anything other than 0.25 mg (or 1.5 mg for the pill)?
    2. 2If I miss doses, which lower dose should I restart on?
    3. 3I am on Ozempic now: how long should I wait, and what Wegovy dose do I start on?
    4. 4If a step makes me sick, should I stay on it for an extra 4 weeks?
    5. 5Which maintenance dose is my target: 1.7 mg, 2.4 mg or, later, 7.2 mg?
    6. 6Would the pill or the injection suit me better?

    The Bottom Line

    You cannot start Wegovy at 0.5 mg under the US label. Both the injection and the pill begin at the lowest dose and step up every four weeks or 30 days because gastrointestinal side effects are common and peak during dose increases. The label lets you go slower, not faster; its new 2026 missed-dose rule requires restarting at a lower dose after two or more missed injections without naming one; and it gives no Ozempic conversion. Those decisions belong to your prescriber.

    FAQ

    Not according to the label. The injection starts at 0.25 mg weekly for 4 weeks, and no trial has tested skipping it. Only your prescriber can decide to depart from the label schedule.

    0.25 mg once weekly for the injection and 1.5 mg once daily for the pill, as of the June 2026 FDA label.

    The Wegovy label gives no conversion from Ozempic, so your prescriber decides based on your current dose, tolerance and time since your last shot. Do not use both at once.

    The label says to consider delaying the next increase for 4 weeks if a dose is not tolerated. Ask your prescriber before changing your schedule.

    The label treats 0.25 mg as a starting step to improve tolerability, not a maintenance dose. Maintenance for adult weight reduction is 2.4 mg or 1.7 mg.

    No. Adolescents 12 and older follow the same 0.25 mg start and 4-week steps, with a maintenance dose of 2.4 mg or 1.7 mg. The 7.2 mg dose is for adults only.

    Sources

    1. 1Novo Nordisk. WEGOVY (semaglutide) injection and tablets, Prescribing Information, revised 06/2026, US Food and Drug Administration, 2026
    2. 2Novo Nordisk. WEGOVY Prescribing Information, revised 05/2026, US Food and Drug Administration, 2026
    3. 3WEGOVY (semaglutide) injection, original 2021 label text, NDC List, 2021
    4. 4Wharton S et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes, Obesity and Metabolism, 2021. doi:10.1111/dom.14551
    5. 516-week flexible vs 8-week semaglutide titration (NCT04447859), trial registry listing; results published in Diabetes Care, 2025
    6. 6Flexible semaglutide titration improves adherence, reduces GI side effects, Epocrates, 2025
    7. 7Novo Nordisk Form 6-K: FDA approval of Wegovy tablets, US Securities and Exchange Commission, 2025
    8. 8FDA approves higher-dose semaglutide under accelerated review program, Pharmacy Times, 2026
    9. 9Switching between weight-loss medications, The Pharmaceutical Journal, 2025 (updated 2026)
    10. 10FDA. Semaglutide injection shortage resolution, US Food and Drug Administration, 2025
    11. 11FDA declares end to semaglutide shortage, STAT, 2025
    12. 12Maker of Wegovy limits supply of obesity drug in the United States, Physician's Weekly, 2023

    This article summarizes the FDA label and published research for general information and is not medical advice. Wegovy trials and the STEP pooled analysis were funded by the manufacturer, Novo Nordisk.

    Diana Gangan

    Author

    Published November 3, 2026
    Share:TwitterFacebook

    Comments (0)

    Be the first to comment on this article.

    More articles

    GLP-1 Drugs Explained: Types, Benefits, Risks, and How They Help With Weight Loss